Brain Blogger Home
  • Home
  • About
    • Editor's Note
    • Contributors
    • Blog Carnival
  • Advertise
  • Archives
    • By Author
    • By Topic
    • By Year
    • By Month
  • Contact
  • Topics
    • Popular
    • Series
    • Video
  • Sitemap
  • Subscribe
  • Contribute
  • Neuroscience & Neurology
  • Psychology & Psychiatry
  • Health & Healthcare
  • More >>
    • BioPsychoSocial Health
    • Brain Blogging Carnival
    • Complementary & Alternative Medicine
    • Drugs & Clinical Trials
    • Drugs & Pharmacology Blog Carnival
    • History of Medicine
    • Law & Politics
    • Living with a Brain Disorder
    • Opinion
    • Site News
    • Stigmatization
Brain Blogger RSS Feed

Brain Blogger Feed & Subscription Options

Follow BB:

Brain Blogger on FaceBook Brain Blogger on twitter Brain Blogger on Flickr Brain Blogger on YouTube
Psychology & Psychiatry
September 7, 2009

New Antipsychotic Agent in the US Market

By Jennifer Gibson, PharmD | Share | 2 Comments
White pills stacked

More than 50 years ago, the first antipsychotic medications appeared in the United States. While these drugs -– fluphenazine, haloperidol, chlorpromazine, and others — were effective in treating a variety of psychiatric conditions, their safety and tolerability presented many drawbacks. It was not until the 1990s when a new class of antipsychotic medications emerged that presented a decreased risk of serious side effects. The newer class of so-called atypical antipsychotics — as opposed to the first-generation “typical” or “conventional” drugs — has not had a new member in more than a decade. Now, the US Food and Drug Administration (FDA) has approved the first new atypical antipsychotic in many years.

Asenapine is an atypical antipsychotic drug approved for the acute treatment of schizophrenia and the acute and extended treatment of mania associated with bipolar disorder. It is indicated for first-line treatment of both conditions, and is the first drug to receive approvals for both conditions simultaneously. The approval of asenapine follows clinical trials evaluating the drug’s efficacy in more than 3000 patients with schizophrenia or bipolar mania. Safety data was evaluated in trials including more than 4500 patients. Some of the trials lasted longer than 2 years.

In studies evaluating the efficacy in acute schizophrenia, doses of 5 mg of asenapine given twice daily were superior to placebo in treating the symptoms of schizophrenia. Doses of 10 mg twice daily significantly reduced mania symptoms associated with bipolar disorder, compared with placebo. Asenapine was found to be non-inferior to other standard atypical antipsychotics used to treat the same conditions.

Like other atypical antipsychotics, asenapine presents a decreased risk of serious side effects compared to typical antipsychotics, but still has the potential for adverse events, including weight gain, extrapyramidal symptoms, and the metabolic syndrome. In head-to-head comparisons, these risks were reduced with asenapine compared to other atypical antipsychotic drugs. Somnolence, dizziness, and movement disorders were also reported with asenapine.

All atypical antipsychotics, including asenapine, carry a black-box warning alerting prescribers and consumers to the risk of death associated with the off-label use of atypical antipsychotics to treat psychotic symptoms associated with dementia. While many clinicians and patients attest to the effectiveness of atypical antipsychotics for treating delirium, their use has never been thoroughly studied or verified. At best, the scientific evidence is inconclusive in this situation.

Asenapine is the first in a handful of new atypical antipsychotic drugs that will likely be appearing on the market in the near future. After more than a decade, clinicians will now have new options to manage their patients’ symptoms.

Asenapine is manufactured by Schering-Plough and will be marketed under the name “Saphris.” It will be available by the end of 2009.

References

Bishara, D., & Taylor, D. (2008). Upcoming Agents for the Treatment of Schizophrenia Drugs, 68 (16), 2269-2292 DOI: 10.2165/0003495-200868160-00002

Peritogiannis, V., Stefanou, E., Lixouriotis, C., Gkogkos, C., & Rizos, D. (2009). Atypical antipsychotics in the treatment of delirium Psychiatry and Clinical Neurosciences DOI: 10.1111/j.1440-1819.2009.02002.x

FDA News Release: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder. 14 August 2009.

Jennifer Gibson, PharmD

Dr. Gibson is a practicing clinical pharmacist and freelance medical writer and editor with experience in researching and preparing scientific publications, developing public relations materials, creating educational resources and presentations, and editing technical manuscripts. Her clients include academic research institutions, international authors, pharmaceutical companies, professional organizations, and public advocacy groups.

Related Articles

  • Antipsychotic Drug Development off Course?
  • Antipsychotics May Decrease the Risk of Suicide
  • Off-Label Use of Psychiatric Medications Common for Veterans
  • Anti-Epileptic Drugs and the Risk of Suicide
  • Should Patients with Schizophrenia Receive Free Medication?
  • Give a Clinical Trial a Try: It’ll Probably Cost Nothing
  • Why Do Schizophrenics Smoke Cigarettes?

2 Responses

  1. Neuroskeptic says:
    September 12, 2009 at 3:00 am

    Blogger The MacGuffin has written some extremely interesting skeptical posts about asenapine and other next-generation antipsychotics.

    Reply
  1. New Antipsychotic Agent in the US Market says:
    September 9, 2009 at 2:47 am

    [...] Original post Share and Enjoy: [...]

    Reply

Leave a Reply

Click here to cancel reply.

Subscribe without commenting


Popular Posts

  • Psychotropics and Youth, Part 1 - The Five Myths
  • Why Some Human Brains Become Leaders, While Others Followers?
  • Goal Setting - Pitfalls and Benefits
  • Clinical Psychologists' Perceptions of Persons with Mental Illness
  • "I Feel Your Pain" - The Neural Basis of Empathy
  • Too Much Information?
  • Ginkgo Biloba Ineffective... Again
  • Journal Retracts Autism Research
  • Speaking in Tongues - A Neural Snapshot
  • Psychotropics and Youth, Part 2 - The Solutions
  • Deep Brain Stimulation - A New Frontier in Psychiatry
  • Pulling The Plug Too Soon?
  • Exercise - It Works For Depression

Future Posts

  • Social Interaction at the Work Place – A Case Study Analysis
  • Climbing Through the Window – How to Heal Past Trauma
  • Tea for Two

Latest Posts

  • Mind your Immune System
  • The Handwriting on the Wall
  • Social Media and Mental Health
  • The Bold and the Beautiful
  • Achieving Enlightened Competence
  • Only the Brain is Worried about Getting Fat
  • Goal Setting – Pitfalls and Benefits
  • Medical Art Imitating Life
  • Female Teachers’ Math Anxiety Negatively Affects Female Students
  • Antidepressants Carry Equal Risks

Comments

  • Helena Vidaurri: Impressive paper! Indeed, we
  • Mike Lisieski: There's some research on testi
  • : yes i totally agree that choco
  • : Enviroment is key and cause of
  • Lisa Geng: Apraxia/dyspraxia is a motor p
  • Brian: Perhaps you might focus more o
  • isabella mori: Brian - you're right, I could
  • Brian: how social media
  • Andrew: Religion is here because men a
  • Diana: I wonder what Deepak Chopra wo
  • Snoa Flaik: I have never read so many moro
  • Evan: My view is that work should be
Sponsored Links

Life insurance, Brain Fitness DVD, San Francisco Doctor, Best vitamins supplements, Online Criminal Justice Degrees, Alcohol Rehab, Tattoo, Cheap Mobile Phone , Retractable Banner Stands , Biotechnology , Breast Cancer , Buy Lipitor , Cystic Fibrosis Signs Symptoms , Pancreatic Cancer Treatment , Pet Insurance , Lung Cancer Treatment , Edgepark Medical , Mattress , Astrology compatibility.

Copyright © 2005-2010 Global Neuroscience Initiative Foundation (GNIF). All Rights Reserved.
Disclaimer | Privacy Policy | RSS Feed | Log in | 1.311s
9rules Network Member